31 Citations (Scopus)

Abstract

Monoclonal antibodies (MoAbs) have now become a successful treatment for selected patients with non-Hodgkin's lymphoma (NHL). Antibody targets most commonly used for the treatment of B-cell NHL include CD20, CD19, and CD22. Unconjugated MoAbs are cytotoxic by several mechanisms, including complement- dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and signal transduction leading to apoptosis. In an attempt to augment the effectiveness of naked antibody preparations, various radioconjugates, immunotoxins, chemotherapeutic agents, or immune-modifiers have been attached to the antibodies. The immunotoxin tested most extensively in clinical trials is B4-blocked ricin (anti-CD19 with a partially blocked ricin toxin). The use of radioimmunoconjugates to augment the effectiveness of unlabeled antibodies has been one of the most popular strategies. Antibodies against these targets have now been chelated with radioconjugates such as 131I or 90Y and tested in recent clinical trials. Radioimmunotherapy has the theoretical advantage over naked antibody therapy or immunotoxin therapy in that the MoAb conjugated with a radioisotope can have a 'cross-fire' effect such that antigen-negative tumor cells adjacent to those expressing the target antigen may also be killed. This may enhance the likelihood of tumor sterilization even in fairly bulky disease. Future studies will focus on testing these antibodies in larger patient populations, sequentially or in combination, and on combining MoAb therapy with standard- or high-dose chemotherapy and hematopoietic stem-cell transplantation.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalSeminars in hematology
Volume36
Issue number4 SUPPL. 6
StatePublished - Oct 28 1999

Fingerprint

Non-Hodgkin's Lymphoma
Antibodies
Immunotoxins
Ricin
Therapeutics
Monoclonal Antibodies
Clinical Trials
Immunoconjugates
Radioimmunotherapy
Antibody-Dependent Cell Cytotoxicity
Hematopoietic Stem Cell Transplantation
B-Cell Lymphoma
Neoplasm Antigens
Radioisotopes
Signal Transduction
Apoptosis
Antigens
Drug Therapy
Population
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Antibody-targeted therapy for low-grade lymphoma. / Vose, Julie Marie.

In: Seminars in hematology, Vol. 36, No. 4 SUPPL. 6, 28.10.1999, p. 15-20.

Research output: Contribution to journalArticle

@article{35a15287f937441695a5773e1eaa78d0,
title = "Antibody-targeted therapy for low-grade lymphoma",
abstract = "Monoclonal antibodies (MoAbs) have now become a successful treatment for selected patients with non-Hodgkin's lymphoma (NHL). Antibody targets most commonly used for the treatment of B-cell NHL include CD20, CD19, and CD22. Unconjugated MoAbs are cytotoxic by several mechanisms, including complement- dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and signal transduction leading to apoptosis. In an attempt to augment the effectiveness of naked antibody preparations, various radioconjugates, immunotoxins, chemotherapeutic agents, or immune-modifiers have been attached to the antibodies. The immunotoxin tested most extensively in clinical trials is B4-blocked ricin (anti-CD19 with a partially blocked ricin toxin). The use of radioimmunoconjugates to augment the effectiveness of unlabeled antibodies has been one of the most popular strategies. Antibodies against these targets have now been chelated with radioconjugates such as 131I or 90Y and tested in recent clinical trials. Radioimmunotherapy has the theoretical advantage over naked antibody therapy or immunotoxin therapy in that the MoAb conjugated with a radioisotope can have a 'cross-fire' effect such that antigen-negative tumor cells adjacent to those expressing the target antigen may also be killed. This may enhance the likelihood of tumor sterilization even in fairly bulky disease. Future studies will focus on testing these antibodies in larger patient populations, sequentially or in combination, and on combining MoAb therapy with standard- or high-dose chemotherapy and hematopoietic stem-cell transplantation.",
author = "Vose, {Julie Marie}",
year = "1999",
month = "10",
day = "28",
language = "English (US)",
volume = "36",
pages = "15--20",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 6",

}

TY - JOUR

T1 - Antibody-targeted therapy for low-grade lymphoma

AU - Vose, Julie Marie

PY - 1999/10/28

Y1 - 1999/10/28

N2 - Monoclonal antibodies (MoAbs) have now become a successful treatment for selected patients with non-Hodgkin's lymphoma (NHL). Antibody targets most commonly used for the treatment of B-cell NHL include CD20, CD19, and CD22. Unconjugated MoAbs are cytotoxic by several mechanisms, including complement- dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and signal transduction leading to apoptosis. In an attempt to augment the effectiveness of naked antibody preparations, various radioconjugates, immunotoxins, chemotherapeutic agents, or immune-modifiers have been attached to the antibodies. The immunotoxin tested most extensively in clinical trials is B4-blocked ricin (anti-CD19 with a partially blocked ricin toxin). The use of radioimmunoconjugates to augment the effectiveness of unlabeled antibodies has been one of the most popular strategies. Antibodies against these targets have now been chelated with radioconjugates such as 131I or 90Y and tested in recent clinical trials. Radioimmunotherapy has the theoretical advantage over naked antibody therapy or immunotoxin therapy in that the MoAb conjugated with a radioisotope can have a 'cross-fire' effect such that antigen-negative tumor cells adjacent to those expressing the target antigen may also be killed. This may enhance the likelihood of tumor sterilization even in fairly bulky disease. Future studies will focus on testing these antibodies in larger patient populations, sequentially or in combination, and on combining MoAb therapy with standard- or high-dose chemotherapy and hematopoietic stem-cell transplantation.

AB - Monoclonal antibodies (MoAbs) have now become a successful treatment for selected patients with non-Hodgkin's lymphoma (NHL). Antibody targets most commonly used for the treatment of B-cell NHL include CD20, CD19, and CD22. Unconjugated MoAbs are cytotoxic by several mechanisms, including complement- dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and signal transduction leading to apoptosis. In an attempt to augment the effectiveness of naked antibody preparations, various radioconjugates, immunotoxins, chemotherapeutic agents, or immune-modifiers have been attached to the antibodies. The immunotoxin tested most extensively in clinical trials is B4-blocked ricin (anti-CD19 with a partially blocked ricin toxin). The use of radioimmunoconjugates to augment the effectiveness of unlabeled antibodies has been one of the most popular strategies. Antibodies against these targets have now been chelated with radioconjugates such as 131I or 90Y and tested in recent clinical trials. Radioimmunotherapy has the theoretical advantage over naked antibody therapy or immunotoxin therapy in that the MoAb conjugated with a radioisotope can have a 'cross-fire' effect such that antigen-negative tumor cells adjacent to those expressing the target antigen may also be killed. This may enhance the likelihood of tumor sterilization even in fairly bulky disease. Future studies will focus on testing these antibodies in larger patient populations, sequentially or in combination, and on combining MoAb therapy with standard- or high-dose chemotherapy and hematopoietic stem-cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0032833105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032833105&partnerID=8YFLogxK

M3 - Article

C2 - 10530712

AN - SCOPUS:0032833105

VL - 36

SP - 15

EP - 20

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4 SUPPL. 6

ER -